Venture Debt, Explained

Venture debt is the strangest instrument in startup finance: loans to companies that lose money, secured by little, underwritten largely to the quality of the investors standing behind the borrower. Used well, it is the cheapest capital a growing startup can take. Used badly, it converts a fundraising problem into a bankruptcy. Every GP needs to understand it, because your portfolio companies will be offered it constantly — and because the lender's incentives are not your incentives.

What venture debt actually is

Venture debt is a term loan (or facility) extended to a venture-backed company, typically sized at 20–35% of the most recent equity round, drawn at or shortly after that round closes. The core underwriting logic is unlike any other credit product:

• The lender is not underwriting cash flow — there usually isn't any.
• The lender is only partly underwriting assets — most startups have few.
• The lender is primarily underwriting the likelihood that the company's investors will fund it again. Lender diligence is substantially diligence on the cap table: who are the VCs, how much dry powder do they have, do they follow on, what are their reserves?

This is why venture debt is a complement to venture equity, never a substitute. The loan is a bridge across the gap between equity rounds, repaid by the next round, an exit, or (rarely) cash flow.

The mechanics

A typical facility looks like this:

• Term: three to four years, usually with an interest-only period of 6–18 months before amortization begins. The I/O period is the product — it defines how much runway the debt actually adds before repayments start eating it back.
• Pricing: a floating or fixed rate meaningfully above prime, plus fees. The headline rate understates true cost.
• Warrants: the lender takes warrant coverage — commonly quoted as a percentage of the loan amount converted into equity at the last round's price. This is the equity kicker that makes the risk math work for the lender, and it is real dilution, if modest.
• Final payment / back-end fees: many facilities carry an additional fee due at maturity or prepayment, which quietly raises the effective cost.
• Security: a blanket lien on company assets, frequently including (or negotiating hard over) intellectual property.
• Covenants: lighter than commercial credit, but watch two clauses. Material adverse change (MAC) clauses let a lender refuse to fund or call default on deterioration judged largely at the lender's discretion. Investor abandonment clauses trigger if the lender believes the VCs have walked away. In stress, these clauses — not the payment schedule — decide the company's fate.

Who lends

The market splits into two lender types with genuinely different behavior:

Banks

Bank lenders — Silicon Valley Bank (now part of First Citizens), Mercury Venture Debt, HSBC Innovation Banking, CIBC Innovation Banking, Stifel Venture Banking, Comerica, Bridge Bank — price cheapest, because deposits fund the loans and the lending relationship anchors a broader banking relationship. The trade-offs: tighter covenants, more conservative sizing, and sensitivity to the bank's own health. SVB's collapse in March 2023 taught the ecosystem that the lender itself is a risk factor — companies and funds now diversify banking relationships as a matter of hygiene.

Dedicated funds and BDCs

Non-bank lenders — Hercules Capital, TriplePoint Capital, Trinity Capital, Horizon Technology Finance, Runway Growth Capital, ORIX Growth Capital, Vistara Growth, and in Europe Kreos Capital (now part of BlackRock), Claret Capital Partners, and Columbia Lake Partners — lend from permanent or fund capital. They price wider than banks but go larger, structure more creatively, and are less covenant-twitchy. Western Technology Investment (WTI) deserves special mention as one of the originators of the asset class, known for underwriting earlier and with more founder-friendly instincts than most.

Adjacent to classic venture debt sits revenue-based and recurring-revenue financing — SaaS Capital, Lighter Capital, Capchase, Founderpath, Espresso Capital, Flow Capital — which advances against ARR with different mechanics (a revenue share or ARR-formula line rather than a warrant-carrying term loan). Useful for capital-efficient SaaS; not a substitute for growth equity.

When venture debt works

The good use cases share one property: the debt extends runway toward a milestone that equity will reward.

• Extending runway between rounds — turning 18 months of cash into 24, so the company raises its Series B after the revenue inflection rather than before it. This is the canonical case: the dilution saved by raising at the higher valuation dwarfs the cost of the debt.
• Insurance alongside a round — closing a facility at the same time as an equity round, when leverage on terms is greatest and the company may never need to draw it.
• Bridging to a known event — a signed term sheet, a large contract, a regulatory approval with a date attached.
• Funding working capital or equipment in businesses with tangible assets — the traditional, lowest-risk end of the market.

When it kills companies

Venture debt fails in one specific, repeatable way: the debt comes due — or amortization begins — exactly when equity is unavailable. A company that borrowed at a peak valuation, missed plan, and now faces amortization plus a down-round market has three bad options: raise structured equity to repay the loan, negotiate with a lender who holds a lien on everything, or sell in distress. The debt did not cause the miss, but it removed the time the company needed to recover from it.

The pattern to underwrite against: debt taken instead of an achievable equity round, debt sized against a valuation the company cannot defend, or debt whose interest-only period ends before the next fundable milestone. If the plan only works if everything goes right, the debt is mispriced insurance.

How a GP should think about it

You will sit on boards where this decision gets made. A working checklist:

• Model the all-in cost — rate, fees, final payments, warrants — against the dilution actually saved at realistic next-round pricing. The comparison is debt cost versus marginal equity dilution, not debt versus nothing.
• Interrogate the maturity math. When does I/O end? What must be true by then? What is the plan if the round slips two quarters?
• Know your lender's downside behavior. Reference the lender the way they referenced you: how did they act with portfolio companies in 2022–2023? Banks and funds behave differently in stress; so do individual lenders within each category.
• Mind the signaling. Drawing a facility to stretch a struggling company telegraphs exactly that to the next round's investors. Debt is best raised from strength.
• Protect the pro rata picture. Warrants dilute everyone; a lender with a lien changes the recovery math on your preference stack in a downside. Your 1x preference sits behind the loan.

Venture debt is a legitimate, often excellent tool — a way to buy time and ownership with cheap capital when the underlying business is compounding. It is also the only instrument in the startup stack with a maturity date and a lien. The GP's job is to make sure the portfolio uses it as leverage on strength, never as a substitute for the harder conversation about whether the next round is really coming.